ML20069A127

Reaffirms Request Re Issuance of Final Design Approval for GESSAR-II.Resolution of Technical Requirements Currently Imposed by NRC Proposed in Submittal Docketed 820222

ML20069A127
Person / Time
Site:	05000447
Issue date:	03/09/1983
From:	Sherwood G GENERAL ELECTRIC CO.
To:	Eisenhut D Office of Nuclear Reactor Regulation
References
MFN-049-83, MFN-49-83, NUDOCS 8303150541
Download: ML20069A127 (2)

Text

e O GENER AL h ELECTRIC NUCLEAR POWER SYSTEMS DIVISION P MFN 049-83 GENERAL ELECgC gg ggg_ygg AVE., SAN JOSE, CALIFORNIA 9s12s March 9,1983 U.S. Nuclear Regulatory Commission Office of Nuclear Reactor Regulation Washington, DC 20555 Attention: Mr. D. G. Eisenhut, Director Division of Licensing Gentlemen:

SUBJECT:

IN THE MATTER OF 238 NUCLEAR ISLANu GENERAL ELECTRIC STANDARD SAFETY ANALYSIS REPORT (GESSAR II) DOCKET N0. STN 50-447 The purpose of this letter is to reaffirm General Electric's request regarding issuance of a Final Design Approval (FDA) for GESSAR II.

After several months of review of this matter with your staff, we have concluded that it is appropriate to issue an FDA in accordance with 10CFR50 Appendix 0andwiththeNuclearRegulatoryCommission's" Statement on Standardization of Nuclear Power Plants , dated August 22, 1978.

In the submittal of GESSAR II which was docketed February 22, 1982, General Electric has.a proposed resolution to all of the technical requirements which are currently imposed by the Staff. These include:

o All current regulatory guides o All current regulatory requirements o TMI-2 requirements o Unresolved Safety Issues o Standard Review Plan (NUREG-0800)

In addition to the above, information submitted on the GESSAR II Docket in 1982 addresses the proposed requirements of SECY-82-01 for severe accidents including the CP/ML rule (FR 1/15/82 and 2/1/82).

General Electric reaffirms its request that the NRC issue a Type-2 FDA in May 1983 to be followed by an FDA supplement when the Staff completes its review of GE's severe accident design. This will then be followed by full Nuclear Power Plant Certification pending the outcome of SECY-82-01.

(

i O!$$oM7 PDR

[d 1

GENERAL U.S. Nuclear Regulatory ion Commiss$ ELECTRIC Page 2 The Type-2 FDA can be issued in accordance with the 1978 Standardization Policy since GESSAR II complies with all regulatory requirements in effect as of the date of docketing for GESSAR II. This would include an effective date for the purposes of applicant referencing for a period of 5 years from the date of the FDA issuance.

I would be pleased to answer any questions on this subject. Please call me at (408) 925-5040 or Rudy Villa on (408) 925-5722.

Very truly yours G enn G. Sherwood, Manager Nuclear Safety and Licensing Operation GGS:hmm/D030710*

cc: W. J. Dircks H. R. Denton R. J. Mattson V. Stello C. O. Thomas F. J. Miraglia K